A wave of noninvasive endometriosis tests is approaching U.S. launch, with companies analyzing biomarkers in endometrial tissue, blood, menstrual fluid and saliva to shorten a diagnosis that today averages nearly a decade. Firms named include Hera Biotech, Proteomics International, NextGen Jane and Ziwig, all aiming for earlier, less invasive diagnosis and better treatment selection. Parallel to diagnostic advances, Cyclana Bio closed a £5 million pre‑seed round to develop tissue‑based disease models and target discovery specifically for endometriosis and women’s health. Cyclana plans to use menstrual fluid and extracellular matrix‑focused modeling to identify early biomarkers and drug targets. These developments could accelerate pipelines for both diagnostics and therapeutics in women’s health by combining improved detection with tissue‑relevant target discovery.